Toxicological considerations of Kampo medicines in clinical use

Toxicology

Volumn 198, Issue 1-3, 2004, Pages 221-228

  Ikegami, Fumio ^a   Fujii, Yuichi ^b   Satoh, Tetsuo ^c  

^a CHIBA UNIVERSITY   (Japan)

^b TSUMURA AND CO   (Japan)

^c Biomedical Research Institute   (Japan)

Author keywords

Clinical use; Crude drug; Interaction; Japanese herbal medicine; Kampo medicine; Toxicity

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALPHA INTERFERON; ANTIBIOTIC AGENT; BAICALIN; BETA INTERFERON; CISPLATIN; CYTOCHROME P450 INHIBITOR; FLAVONOID; FUROCOUMARIN DERIVATIVE; GLYCYRRHIZIC ACID; HERBACEOUS AGENT; IRINOTECAN; KAMPO; LEVODOPA; LEVOFLOXACIN; MINERAL; NICARDIPINE; OFLOXACIN; PHENYTOIN; PREDNISOLONE; THEOPHYLLINE; WARFARIN;

ACUTE TOXICITY; ALLERGIC REACTION; BRONCHITIS; CHRONIC TOXICITY; CONFERENCE PAPER; DIARRHEA; DRUG ABSORPTION; DRUG EFFECT; DRUG METABOLISM; DRUG UTILIZATION; FEVER; FOOD; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; GRAPE JUICE; HERBAL MEDICINE; HUMAN; INFLUENZA; JAPAN; LIVER INJURY; LYMPHADENITIS; MUTAGENESIS; NONHUMAN; PLANT; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; TERATOGENICITY; TOXICITY; VOMITING;

ANIMALS; DRUG INTERACTIONS; DRUGS, CHINESE HERBAL; HUMANS; JAPAN; MEDICINE, KAMPO;

ANIMALIA; CITRUS X PARADISI;

EID: 2342616822     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2004.01.029     Document Type: Conference Paper

References (53)

1. Armanini D., Fiore C., Mattarello M.J., Bielenberg J., Palermo M. History of the endocrine effects of licorice. Exp. Clin. Endocrinol. Diabetes. 110:2002;257-261
2. Aso S., Horiwaki S., Mashiba C., Tatsumi Y., Suzuki A. Teratogenicity study of orally administered Sho-saiko-to in rats. Pharmacometrics. 44:1992;659-673
3. Chan, K., Cheung, L., 2000. Examples of interactions between Chinese herbal medicinal products and orthodox drugs. In: Interactions Between Chinese Herbal Medicinal Products and Orthodox Drugs. Harwood Academic Publishers, Amsterdam, The Netherlands, pp. 57-97.
4. Coon J.T., Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Safety. 25:2002;323-344
5. Dergal J.M., Gold J.L., Laxer D.A., Lee M.S., Binns M.A., Lanctot K.L., Freedman M., Rochon P.A. Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging. 19:2002;879-886
6. Ebisuno S., Hirano A., Kyoku I., Ohkawa T., Iijima O., Fujii Y., Hosoya E. Protective effects of Juzentaiho-to (TJ-48) on the toxic side effects of CDDP and antitumor effects with CDDP on murine bladder tumor (MBT-2). J. Jpn. Soc. Cancer Ther. 24:1989;1305-1312
7. Fugh-Berman A. Herb-drug interactions. Lancet. 355:2000;134-138
8. Fukuda K., Suzuki R., Kido T., Yamamoto M., Komatsu Y. Synergistic effects of Sho-saiko-to and interferons in vivo. J. Traditional Med. 12:1995;414-415
9. Fukuda K., Ohta T., Oshima Y., Ohashi N., Yoshikawa M., Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice, furocoumarin dimmers as components of drug interaction. Pharmacogenetics. 7:1997;391-396
10. Guo L.-Q., Taniguchi M., Xiao Y.-Q., Baba K., Ohta T., Yamazoe Y. Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn. J. Pharmacol. 82:2000;122-129
11. Hasegawa T., Yamaki K., Nadai M., Muraoka I., Wang L., Takagi K., Nabeshima T. Lack of effect of Chinese medicines on bioavailability of ofloxacin in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 32:1994;57-61
12. Hasegawa T., Yamaki K., Muraoka I., Nadai M., Takagi K., Nabeshima T. Effect of traditional Chinese medicines on pharmacokinetics of levofloxacin. Antimicrob. Agents Chemother. 39:1995;2135-2137
13. Homma M., Oka K., Niitsuma T., Itoh H. A novel 11beta-hydroxysteroid dehydrogenase inhibitor contained in Saiboku-to, a herbal remedy for steroid-dependent bronchial asthma. J. Pharm. Pharmacol. 46:1994;305-309
14. Hosoya J., Nagaoka H., Nakagawa Y. Effects of Sho-saiko-to, Keishi-ka-shakuyaku-to and its simultaneous use on the pharmacokinetics of phenytoin in rabbit. Jpn. J. Hosp. Pharm. 19:1993;203-208
15. Iijima, O., Fujii, Y., Aburada, M., Hosoya, E., 1988. Protective effects of Juzentaiho-to (TJ-48) on the adverse effects of some antitumor agents. In: Recent Advances in the Pharmacology of Kampo Medicines. Excepta Medica, Ltd., Tokyo, pp. 353-358.
16. Ikegami, F., 2001. Herbal drugs in Kampo medicine in present-day Japan. In: Emerging Drugs, vol. 1. Molecular Aspects of Asian Medicines. PJD Publication Ltd., New York, USA, pp. 489-507.
17. Ikegami F., Fujii Y., Ishihara K., Satoh T. Toxicological aspects of Kampo medicines in clinical use. Chem-Biol. Interact. 145:2003;235-250
18. Imai T., Sakai T., Ohtake H., Azuma H., Otagiri M. In vitro and in vivo evaluation of the enhancing activity of glycyrrhizin on the intestinal absorption of drugs. Pharm. Res. 16:1999;80-86
19. Ishihara K., Kushida H., Yuzurihara M., Wakui Y., Kitada M. Interaction of drugs and Chinese herbs, pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica. J. Pharm. Pharmacol. 52:2000;1023-1029
20. Itoh T., Murai S., Yoshida H., Masuda Y., Saito H., Hatakeyama T., Yonekura H. Chronic toxicity test of Sho-saiko-to in rats. Pharmacometrics. 23:1982;279-285
21. Iwai A., Sugiyama Y., Kawakami A., Ueno K. Effect of Saiboku-to on theophylline disposition and laboratory findings. Jpn. J. TDM. 8:1991;57-64
22. Kanitani M., Maemura S., Yamada S., Minematsu S., Kuboniwa H., Tsuchiya N., Fujii Y. A single oral dose toxicity study and a 13-week repeated dose study with a 4-week recovery period of Tsumura Sairei-to (TJ-114) in rats. Jpn. Pharmacol. Ther. 23:1995;371-387
23. 2 and water absorption in the rat. Jpn. J. Pharmacol. 75:1997;407-413
24. Katsumata Y., Shimazu H., Takamatsu T., Matsumoto H., Minematsu S., Maemura S. Reproductive and developmental toxicity study of Tsumura Keishi-bukuryo-gan (TJ-25) in rats by oral administration, single study design. Jpn. Pharmacol. Ther. 25:1997;73-87
25. Klerk G.J., Nieuwenhuis M.G., Beutler J.J. Hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum. Br. Med. J. 314:1997;731-732
26. Kobayashi Y., Minematsu S., Maemura S., Perry C.J., Mulhern M. A single oral dose toxicity study and a 13-week repeated dose study with a 4-week recovery period of Tsumura Shigyaku-san (TJ-35) in rats. Jpn. Pharmacol. Ther. 23:1995a;191-207
27. Kobayashi Y., Minematsu S., Maemura S., Atkinson C., Mulhern M. A single oral dose toxicity study and a 13-week repeated dose study with a 4-week recovery period of Tsumura Keishi-bukuryo-gan (TJ-25) in rats. Jpn. Pharmacol. Ther. 23:1995b;151-168
28. Koizumi K., Iijima H., Nohmi M., Nakayama S., Oguchi K. Effect of Byakushi and Ogon on the hepatic drug metabolizing enzymes in rats. Folia Pharmacol. Jpn. 104:1994;413-419
29. Konishi H., Yasuda Y., Abe H., Arichi S., Tanimura T. Effects of Sho-saiko-to on pregnant rats and development of their fetuses. J. Traditional Med. 3:1986;111-118
30. Kuboniwa H., Katayama M., Maemura S., Minematsu S., Onishi M. Mutagenicity studies of Sho-saiko-to (TJ-9). Jpn. Pharmacol. Ther. 27:1999a;13-19
31. Kuboniwa H., Katami M., Maemura S., Minematsu S., Onishi M., Saigou K., Agura F. Mutagenicity studies of Saiko-keishi-to (TJ-10). Jpn. Pharmacol. Ther. 27:1999b;101-107
32. Kuboniwa H., Maemura S., Mimematsu S., Onishi M., Saigou K., Aruga F., Miwa Y. Mutagenicity studies of Keishi-bukuryo-gan (TJ-25). Jpn. Pharmacol. Ther. 27:1999c;95-100
33. Kuboniwa H., Maemura S., Minematsu S., Saigou K., Nagasawa Y., Miwa Y. Mutagenicity studies of Shakuyaku-kanzo-to (TJ-68). Jpn. Pharmacol. Ther. 27:1999d;57-63
34. Lo A.C.T., Chan K., Yeung J.H.K., Woo K.S. Danggui (Angelica sinensis) affects the pharmacodynamics but not the pharmacokinetics of warfarin in rabbits. Eur. J. Drug Metab. Pharmacokinet. 20:1995;55-60
35. Makino T., Wakushima H., Okamoto T., Okukubo Y., Deguchi Y., Kano Y. Pharmacokinetic interactions between warfarin and kangen-karyu, a Chinese traditional medicine, and their synergistic action. J. Ethnopharmacol. 82:2002;35-40
36. Mëenpää J., Sigusch H., Raunio H., Syngelmä T., Vuorela P., Pelkonen O. Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem. Pharmacol. 45:1993;1035-1042
37. Minematsu S., Atkinson J.E., Bolte H.F., Sakai H., Fujii Y. A subchronic (3-month) oral toxicity study of Tsumura Sho-saiko-to (TJ-9) in the rat via oral gavage administration with a 4-week recovery period. Pharmacometrics. 43:1992;19-42
38. Minematsu S., Taki M., Watanabe M., Kobayashi Y., Tsuchiya N., Harada Y., Izumi K., Imamura S., Fujii Y. A single oral dose toxicity study and a 13-week repeated dose study with a 4-week recovery period of Tsumura Saiko-keishi-to (TJ-10) in rats. Jpn. Pharmacol. Ther. 23:1995a;33-52
39. Minematsu S., Maemura S., Perry C.A., Mulhern M. A single oral dose toxicity study and a 13-week repeated dose study with a 4-week recovery period of Tsumura Saiboku-to (TJ-96) in rats. Jpn. Pharmacol. Ther. 23:1995b;315-330
40. Narita M., Nagai E., Hagiwara H., Aburada M., Yokoi T., Kamataki T. Inhibition of β-glucuronidase by natural glucuronides of Kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica. 23:1993;5-10
41. Obermeier M.T., White R.E., Yang C.S. Effects of bioflavonoids on hepatic P450 activities. Xenobiotica. 25:1995;575-584
42. Ohta T., Maruyama T., Nagahashi M., Miyamoto Y., Yamazoe Y., Tsukamoto S. Paradisin C, a new CYP3A4 inhibitor from grapefruit juice. Tetrahedron. 58:2002;6631-6635
43. Page R.L. II, Lawrence J.D. Potentiation of warfarin by Dong Quai. Pharmacotherapy. 19:1999;870-876
44. Sakai M., Imai T., Ohtake H., Azuma H., Otagiri M. Simultaneous use of sodium deoxycholate and dipotassium glycyrrhizinate enhances the cellular transport of poorly absorbed compounds across Caco-2 cell monolayers. J. Pharm. Pharmacol. 51:1999;27-33
45. Sameshima H., Unno T., Hirakawa K., Ogino F., Takase H., Nurimoto S. Acute and subacute toxicity of Sho-saiko-to. Pharmacometrics. 33:1987;793-808
46. Shimazu H., Katsumata Y., Takamatsu T., Matsumoto H., Minematsu S., Maemura S. Reproductive and developmental toxicity study of Tsumura Sho-saiko-to (TJ-9) in rats by oral administration, single study design. Jpn. Pharmacol. Ther. 25:1997;29-43
47. Shinyanagi M., Nakayama S., Oguchi K. Effects of Sino-Japanese herbs in the family Umbelliferae on the hepatic drug metabolizing enzymes and lipid peroxidation in rats. Folia Pharmacol. Jpn. 99:1992;115-121
48. Sugimoto K., Ohmori M., Tsuruoka S., Nishiki K., Miyamori I., Fujimura A. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin. Clin. Pharmacol. Ther. 70:2001;518-524
49. Takasuna K., Kasai Y., Kitano Y., Mori K., Nagai E., Kamataki T. Protective effects of Kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res. 86:1995;978-984
50. Uno T., Ohkubo T., Sugawara K., Higashiyama A., Motomura S. Effects of Shigyaku-san (TJ-35) on pharmacokinetics and pharmacodynamics of nicardipine. Res. Drug Actions Interact. 21:1998;139-145
51. World Health Organization (WHO), 1999. In: WHO Monographs on Selected Medicinal Plants, vol. 1. World Health Organization, Geneva, Switzerland.
52. Yamasaki K., Shiraishi K., Imatanaka N., Nagai K., Tatsumi Y., Miura O., Suzuki A. One-year chronic oral toxicity study of Sho-saiko-to in rats. Pharmacometrics. 39:1990;405-426
53. Yanagisawa E., Ishihara K., Imai K., Maemura S., Fujii Y., Aburada M., Oyama T. Toxicokinetics of Sho-saiko-to (TJ-9) in rats following multiple dosing for 13 weeks. Pharmacometrics. 44:1992;649-657